Abstract
Re-programming of metabolic pathways is a hallmark of pathological changes in cancer cells. The expression of certain genes that directly control the rate of key metabolic pathways including glycolysis, lipogenesis and nucleotide synthesis is dysregulated for the adaptation and progression of tumor cells to become more aggressive phenotypes. The pentose phosphate pathway controlled by glucose- 6-phosphate dehydrogenase (G6PD) has been appreciated largely to its role as a provider of reducing power and ribose phosphate to the cell for maintenance of redox balance and biosynthesis of nucleotides and lipids. Recently, G6PD has been revealed to be involved in apoptosis, angiogenesis, and the efficacy to anti-cancer therapy, making it as a promising target in cancer therapy. This review summarizes the information about the latest progress relating the activity of the G6PD to cell proliferation, angiogenesis, and resistance to therapy in cancer cells, and discusses the possibility of G6PD as a diagnostic biomarker of cancer and the therapeutic potentials of G6PD inhibitors in cancer treatment. The available data show that G6PD plays a critical role in survival, proliferation, and metastasis of cancer cells. Development of potent and selective G6PD inhibitors would provide novel opportunity for cancer therapy.
Keywords: Cancer metabolisms, glucose-6-phosphate dehydrogenase, NADPH, oxidative stress, reactive oxygen species, therapeutic target.
Anti-Cancer Agents in Medicinal Chemistry
Title:Glucose-6-phosphate Dehydrogenase: a Biomarker and Potential Therapeutic Target for Cancer
Volume: 14 Issue: 2
Author(s): Chunhua Zhang, Zheng Zhang, Yuechun Zhu and Suofu Qin
Affiliation:
Keywords: Cancer metabolisms, glucose-6-phosphate dehydrogenase, NADPH, oxidative stress, reactive oxygen species, therapeutic target.
Abstract: Re-programming of metabolic pathways is a hallmark of pathological changes in cancer cells. The expression of certain genes that directly control the rate of key metabolic pathways including glycolysis, lipogenesis and nucleotide synthesis is dysregulated for the adaptation and progression of tumor cells to become more aggressive phenotypes. The pentose phosphate pathway controlled by glucose- 6-phosphate dehydrogenase (G6PD) has been appreciated largely to its role as a provider of reducing power and ribose phosphate to the cell for maintenance of redox balance and biosynthesis of nucleotides and lipids. Recently, G6PD has been revealed to be involved in apoptosis, angiogenesis, and the efficacy to anti-cancer therapy, making it as a promising target in cancer therapy. This review summarizes the information about the latest progress relating the activity of the G6PD to cell proliferation, angiogenesis, and resistance to therapy in cancer cells, and discusses the possibility of G6PD as a diagnostic biomarker of cancer and the therapeutic potentials of G6PD inhibitors in cancer treatment. The available data show that G6PD plays a critical role in survival, proliferation, and metastasis of cancer cells. Development of potent and selective G6PD inhibitors would provide novel opportunity for cancer therapy.
Export Options
About this article
Cite this article as:
Zhang Chunhua, Zhang Zheng, Zhu Yuechun and Qin Suofu, Glucose-6-phosphate Dehydrogenase: a Biomarker and Potential Therapeutic Target for Cancer, Anti-Cancer Agents in Medicinal Chemistry 2014; 14 (2) . https://dx.doi.org/10.2174/18715206113136660337
DOI https://dx.doi.org/10.2174/18715206113136660337 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Up-regulation of microRNA-16 in Glioblastoma Inhibits the Function of Endothelial Cells and Tumor Angiogenesis by Targeting Bmi-1
Anti-Cancer Agents in Medicinal Chemistry How is Gene Transfection Able to Improve Current Chemotherapy? The Role of Combined Therapy in Cancer Treatment
Current Medicinal Chemistry Uptake of [¹⁸F]tetrafluoroborate in MCF-7 Breast Cancer Cells is Induced after Stimulation of the Sodium Iodide Symporter
Current Cancer Drug Targets Targeting p73 - a Potential Approach in Cancer Treatment
Current Pharmaceutical Design Discovery of Potent Natural-Product-Derived SIRT2 Inhibitors Using Structure- Based Exploration of SIRT2 Pharmacophoric Space Coupled With QSAR Analyses
Anti-Cancer Agents in Medicinal Chemistry Hemichannels in Cerebral Ischemia
Current Molecular Medicine Targeting Ovarian Cancer-Initiating Cells
Anti-Cancer Agents in Medicinal Chemistry ATP Citrate Lyase (ACLY): A Promising Target for Cancer Prevention and Treatment
Current Drug Targets Proteomics and Epigenetic Mechanisms in Stem Cells
Current Proteomics Autologous Formalin-Fixed Tumor Vaccine
Current Pharmaceutical Design Human Amnion–Derived Cells as a Reliable Source of Stem Cells
Current Molecular Medicine Non-Coding RNA in Brain Development and Disorder
Current Medicinal Chemistry Application of Carbon Nanotubes In Drug Delivery of Non-cancerous Diseases: A Review
Current Pharmaceutical Design Reactions of Hydrazones with Lead Tetraacetate in Organic Synthesis
Current Organic Chemistry Natural Products as Anticancer Agents
Current Drug Targets Promises of Nanotechnology for Drug Delivery to Brain in Neurodegenerative Diseases
Current Nanoscience Recent Advances in Understanding and Exploiting the Activation of Anthracyclines by Formaldehyde
Current Medicinal Chemistry - Anti-Cancer Agents Voltage-Gated Ion Channels, New Targets in Anti-Cancer Research
Recent Patents on Anti-Cancer Drug Discovery The Epithelial-Mesenchymal Transition and Cancer Stem Cells: Functional and Mechanistic Links
Current Pharmaceutical Design Transdermal Drug Delivery: A Step towards Treatment of Cancer
Recent Patents on Anti-Cancer Drug Discovery